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Recent studies have identified a series of estrogen receptor (ER)-
interacting peptides that recognize sites that are distinct from the
classic coregulator recruitment (AF2) region. Here, we report the
structural and functional characterization of an ER-specific pep-
tide that binds to the liganded receptor in an AF2-independent
manner. The 2-Å crystal structure of the ERpeptide complex
reveals a binding site that is centered on a shallow depression on
the -hairpin face of the ligand-binding domain. The peptide binds
in an unusual extended conformation and makes multiple contacts
with the ligand-binding domain. The location and architecture of
the binding site provides an insight into the peptide’s ER subtype
specificity and ligand interaction preferences. In vivo, an engi-
neered coactivator containing the peptide motif is able to strongly
enhance the transcriptional activity of liganded ER, particularly in
the presence of 4-hydroxytamoxifen. Furthermore, disruption of
this binding surface alters ER’s response to the coregulator TIF2.
Together, these results indicate that this previously unknown
interaction site represents a bona fide control surface involved in
regulating receptor activity.
coregulator  phage display  structure
The estrogen receptor (ER) functions as a ligand-activatedtranscription factor and is responsible for mediating the phys-
iological effects of the steroid hormone 17-estradiol (E2). Tran-
scriptional activation is facilitated by two distinct activation func-
tions (AF), the constitutively active AF1 located at the N terminus
of the receptor and a ligand-dependent AF2 that resides in the
C-terminal ligand-binding domain (LBD) (1), which recruit a range
of coregulatory protein complexes to the DNA-bound receptor (2).
ER agonists promote association with coactivators, whereas antag-
onists favor recruitment of corepressors.
The LBD serves as the major interaction point between nuclear
receptors (NRs) and coregulatory proteins. Coactivator recruit-
ment is mediated by short -helical, leucine-rich LxxLL consensus
motifs (NR-box) that bind to the AF2 region of the LBD (3–5).
Structural analysis ofNRLBDs has established that agonist binding
stabilizes a receptor conformation in which elements of AF2 form
a hydrophobic groove that can accommodate the LxxLL motifs
found within coactivators (6–8). In contrast, ER antagonists affect
the positioning of theAF2’smobile C-terminal helix (H12), thereby
disrupting the LxxLL-binding site and preventing coactivator re-
cruitment (7, 9). The resultant antagonist-induced conformation
favors recruitment of corepressor complexes (10). Although the
details of corepressor binding to ERLBD are not known, antago-
nist-induced displacement of H12 in other NRs promotes core-
pressor recruitment to an interaction surface that overlaps with the
AF2 groove (11–13).
Although this conformational mechanism can be used to ratio-
nalize the differential recruitment of coactivators and corepressors
to a common surface onER, it is not immediately apparent how this
alone can account for the diverse pharmacology of selective ER
receptor modulators (SERMs). SERMs, such as raloxifene and
4-hydroxytamoxifen (OHT), are a class of synthetic ER ligands that
exhibit tissue-dependent pharmacology, imitating the action of
estrogens in certain tissues while opposing their action in others
(14). These compounds appear to elicit their effects by inducing
distinct conformational changes in ER that favor interaction with
specific subsets of coactivators (15). The mechanisms of such
coactivator binding are unclear but are likely to involve recognition
surfaces, which are unrelated to AF2, that are revealed in response
to a particular modulator.
The screening of random peptide libraries is a powerful method
for isolatingmotifs that mimic protein–protein interaction surfaces.
Phage display techniques using both focused and random peptide
libraries have been used to investigate the interaction of coregula-
tors with liganded ER (13, 16–19). These studies have isolated a
number of short peptides with characteristic sequence motifs that
specifically recognize different liganded states of ER. Such pep-
tides, in addition to acting as conformational probes (16), have been
shown to interfere with receptor activity both in vitro and in
cell-based assays (18, 19). These observations have led to the
suggestion that such motifs represent biologically relevant interac-
tion modules or, alternatively, that they mimic receptor–cofactor
interactions. Although some of the isolated motifs are directed to
the region around ER’s AF2 binding groove, several possess
previously undescribed consensus sequences and appear to interact
with distinct regions of the receptor.
To address whether ERLBD harbors additional protein–protein
interaction sites, we have studied anER interactionmotif that binds
specifically to ER. The 11-residue peptide antagonist, referred to
as II, was initially isolated from a random peptide phage display
library by using E2- or OHT-bound ER and found to interact in
the presence of a broad spectrum of receptor modulators (16). In
this study, we have used a combination of techniques to both
delineate the II binding site on ERLBD and demonstrate that
this surface is involved in ER’s response to certain ligands.
Materials and Methods
Protein Expression and Purification. The H12 truncated mutant
(ERH12) used for structural analysis was generated by inserting
a stop codon after Val-533 in a pET15b-ERLBD construct (20).
ERH12 was expressed in Escherichia coli strain C41 (DE3).
ERH12 was extracted from inclusion bodies with a buffer (150
mM NaCl1 mM EDTA2 mM DTT10% glycerol1 mM
PMSF50 mM Tris, pH 8.0) containing 1% (wtvol) Zwittergent
3-12. The detergent was removed by dialysis, and the extract was
applied to an E2–Sepharose column. The E2-affinity matrix was
prepared as described (21). Bound ERH12 was carboxymethy-
lated overnight with 10 mM iodoacetic acid and eluted with 50 M
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OHT in a buffer containing 1 mM DTT, 1 mM EDTA, 250 mM
NaSCN, and 25 mM Tris (pH 8.5). ERH12 was further purified
by using ion exchange chromatography. Pooled fractions containing
ERH12 were combined with a 1.5-fold molar excess of II
peptide and concentrated to 10 mgml. Additional peptide was
added to obtain a final peptideLBD molar ratio of 3:1.
Crystallization and Structure Determination. Hanging drops com-
posed of equal volumes of ERH12-OHT-II complex and
reservoir solution [20% (wtvol) polyethylene glycol (PEG) 2000
monomethyl ether (Mme)620 mM sodium formate3% (wtvol)
glucose in 100mMTris, pH 8.0] were equilibrated against reservoir
solution at 19°C. Crystals were cryoprotected in mother liquor
containing 32.5% (wtvol) PEG 2000 Mme and vitrified in liquid
nitrogen. Crystals belong to space group P212121 and have a single
LBD homodimer per asymmetric unit. Diffraction data, collected
to a resolution of 2 Å on beamline ID29 at the European Synchro-
tron Radiation Facility (Grenoble, France), were indexed, reduced,
and scaled by using the HKL suite of programs (22). The structure
was solved by molecular replacement using AMORE (23). Initial
electron densitymaps clearly indicated the position ofOHTand the
II peptide. The structure was refined with REFMAC5 (24) using all
available data. All model building was carried out with QUANTA
(Accelrys, San Diego). The final model has an Rcryst of 18.7% and
aRfree of 21.9%.Data collection and refinement statistics are shown
in Table 1, which is published as supporting information on the
PNAS web site.
Surface Plasmon Resonance (SPR). Measurements were performed
by using a BIAcore X instrument and streptavidin-coated sensor
chips. Experiments were carried out as described (8). Biotinylated
II peptide (SGSGLTSRDFGSWYA)was immobilized to variable
responses (60–160 relative units). Qualitative binding experiments
with liganded ERLBD and LBD mutants were performed by
flowing each complex (1 M dimeric concentration) over the II
chip for 2 min at 5 lmin1. A sensor chip comprising an immo-
bilized biotinylated SRC2–2 peptide (EKHKILHRLLQDS) (8)
was used as a control binding surface to assess the structural
integrity of the LBDmutants.Methods used for construction of the
LBD mutants, the kinetic analysis and preparation of protein used
for SPR studies are described in Supporting Text, which is published
as supporting information on the PNAS web site.
Mammalian Two-Hybrid and Reporter Assays. Details of the ER and
TIF2 expression plasmids used are described in Supporting Text.
Mammalian two-hybrid experiments were carried out as described
(19). For the transcriptional assays with the engineered TIF2
coactivator, Cos-7 cells were cotransfected with expression vectors
(pSG5) for wild-type ER and either TIF2-NR12 or TIF2II
togetherwith the estrogen responsive 3ERE-TATA-luc reporter.
Experiments were performed in triplicate and contained 30 ng of
ER construct, 30 ng of -gal construct, 150 ng of reporter
construct, and 150 ng of TIF2 expression plasmid. After transfec-
tion, cells were treated with 10 nM E2, 100 nM OHT, or dimeth-
ylsulphoxide for 16 h before analyzing luciferase and -gal activity.
For the transcriptional assays comparing wild-type and mutant
(ERG442H) receptor activity, Cos-7 cells were cotransfectedwith
expression vectors (pSG5 or Gal4DBD) for wild-type ER, ER
G442H, Gal4-tagged ER DEFH12, or Gal4-tagged ER
DEFG442HH12 and either empty expression vector (pSG5) or
TIF2wt expression vector together with either the estrogen respon-
sive 3 ERE-TATA-luc reporter or the Gal4 responsive reporter
5 UAS-TATA-luc. Each triplicate contained 30 ng of ER
construct, 30 ng of-gal construct, 150 ng of reporter construct, and
30 ng of TIF2 expression plasmid. After transfection, cells were
treated with 100 nM OHT or dimethylsulphoxide for 16 h before
analyzing luciferase and -gal activity.
Results
II Peptide Motif Interacts Specifically with Liganded ERLBD. Pre-
vious reports of II binding to ER showed that the interaction
occurs within the C-terminal LBD region between residues 282 and
535 (18). To confirm that II interacts with the alkylated LBD used
for crystallization (9), we carried out real-time analysis of the
binding between ERLBD and the II interaction motif by using
SPR. A biotinylated II peptide immobilized onto a streptavidin-
coated sensor chip can specifically recognise various liganded forms
of ERLBD (Fig. 5A, which is published as supporting information
on the PNAS web site). The II peptide interacts with ERLBD
bound to both agonists (E2, diethylstilbestrol, genistein) and an
AF2 antagonist (OHT). The ligand interaction preference is similar
to that observed for full-length ER (16). As previously reported
(18),II binding is not dependent onAF2, because an LBDmutant
lacking the C-terminal activation helix H12 (ERH12) retains its
ability to bind to the II peptide (Fig. 5B). Kinetic analysis
demonstrates that theII peptide binds toERLBDwithmoderate
affinity and has an apparent dissociation constant (Kd) of 34 M
(Fig. 5C).
Structure of the ERLBD-II Peptide Complex. To get a better
understanding of the nature and location of the II-binding site on
ER, we cocrystallized ERLBD with an 11-residue peptide
corresponding to the II interaction motif (LTSRDFGSWYA).
Initial crystallization trials with various ERLBD-II complexes
did not yield crystals suitable for structural analysis. Based on our
observations that II binding was independent of H12, we also set
up trials using the truncated ERH12 mutant. The resultant
complex, liganded with OHT, produced well diffracting crystals.
The overall ER12 mutant structure is very similar to that seen
previously for ERLBD in complex with either E2 (9) or OHT (7)
(rms deviation for -carbons of 0.51 and 0.69 Å, respectively).
Removal of H12 and the preceding loop has no discernable effect
on the integrity of the LBD fold.
Peptide-Binding Site. The ERH12-OHT-II peptide complex
crystallises with a single LBD homodimer in the asymmetric unit.
Each monomer within the homodimer interacts with a peptide
motif (Fig. 6A, which is published as supporting information on the
PNAS web site). Difference Fourier maps revealed well defined
electron density for the peptide, allowing us to model the entire
11-residue II sequence (Fig. 6B). The II motif binds across the
-hairpin face of the LBD (Fig. 1A). The interaction site is centered
on a shallowdepression betweenH2,H6, andH9 that surrounds the
entrance of the solvent-filled channel that leads to the buried
hormone-binding cavity. This surface lies diametrically opposite the
receptor’s AF2 coactivator recruitment site (Fig. 1B). Residues
from H2, the H2–H3 loop, H6, the S1–S2 -hairpin, H8–H9 loop,
H9, and H10 contribute to an extensive binding surface (10 Å by 24
Å long).
The II peptide adopts an extended conformation that closely
matches the surface topology of the LBD (Fig. 2A). Residues
Leu-1–Phe-6 runparallel to the S1 strandwith residues Ser-3–Asp-5
adopting a 310 helical conformation.AtGly-7, the peptide backbone
turns 90° and climbs toward H10. This bent conformation is
stabilized by an intramolecular interaction between the backbone
carbonyl of Phe-6 and the indole nitrogen of Trp-9. Gly-7 appears
to fulfil a structural role because of the strained backbone dihedral
angles required at this position.
LBD recognition is mediated by an extensive network of
hydrogen-bonded and nonpolar interactions. No single interaction
appears to dominate, and the observed peptide conformation is
reliant on multiple intra- and intermolecular contacts. Binding of
the II motif buries 650 Å2 of predominantly hydrophobic surface
area on the LBD. Residues from the peptide make a total of eight
direct hydrogen bonds with the LBD (Fig. 2B). The N terminus of
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the peptide is anchored to the loop between H2 and H3. Ser-3
is completely buried and plugs the entrance to the solvent
channel. Contacts between the central portion of the motif and
the LBD are mainly hydrophobic in nature (Fig. 2C). Phe-6 lies
at the periphery of the site and packs against the aliphatic side
chain of Arg-394, a residue that plays a critical role in recognition
of the phenolic hydroxyl of ER ligands. Trp-9 is thrust toward the
body of the LBD and packs against Gly-442 (H9) and Trp-393
(H6). Residues at the N-terminal end of H9 (Gln-441, Gly-442,
Glu-443, and Glu-444) make multiple hydrogen-bonded inter-
actions with C-terminal half of the II motif (Fig. 2B). The
C-terminal end of the motif is anchored by two separate inter-
actions. The main chain amides of Tyr-11 and Ala-12 interact
with carboxylate side chain of Glu-443. In addition, the side
chain of Tyr-10 projects over the H8–H9 loop and binds in a
narrow cleft between Gln-441 and Ala-493 (Fig. 2 A–C).
Comparison with all other ERLBD ligand complexes demon-
strates that the II-binding site is structurally invariant. his
observation underlies II’s ability to bind to any agonist-, AF2
antagonist-, or pure antagonist-bound ER. The motif’s specificity
for ER appears to derive from the fact that parts of the site are
poorly conserved in ER and other NRs (Fig. 2D). In particular,
sequence changes at the N-terminal end of H9 are likely to affect
II binding. In ER, Gly-442 and Glu-443 are replaced by a
histidine and lysine, respectively.
Mutagenesis Studies of LBD Binding to II. To validate the location
of the interaction site delineated in the crystal structure and to
investigate the ER-specific nature of the interaction, we made a
series of single site LBD mutants and evaluated II-binding by
using SPR.Choice of appropriatemutationswas complicated by the
fact that residues lining the binding site fulfil key roles in main-
taining the structural integrity of the LBD. Consequently, only
residues that anchored the termini of the II motif were targeted
(I326, Q441, G442, E443). These residues were either replaced with
alanine (Q441, E443) or with the corresponding ER residue type
(I326H, G442H, E443K).
Fig. 2E shows the binding response of each mutant (liganded to
E2) to theII sensor chip. Changes at all sites were poorly tolerated
and severely impaired the interaction. In contrast, binding of the
mutants to an immobilized LxxLL peptide, derived from the
NRbox2 region of TIF2 (SRC2–2) (8), was similar to that observed
for the wild-type LBD (Fig. 2E Inset). These control binding
experiments suggest that none of the mutations impacted on the
LBD’s ability to bind E2 and adopt an activated conformation
capable of recruiting coactivator. The mutant binding data
indicates that the inability of the II motif to interact with ER
derives primarily from steric clashes with the bulkier residues
found at positions 326 and 442 (279 and 394 in ER) in this
isoform (Fig. 2D).
Binding of II Peptide in Mammalian Cells. Previous studies have
demonstrated II binding to ER in a cellular context (18, 25). To
confirm that the II binding site observed in the crystal structure
of theLBDcomplex ismaintained in the full-length receptor in vivo,
we investigated the interaction by using a well established mam-
malian two-hybrid (M2H) assay (19). As demonstrated in Fig. 3A,
the II peptide interacted with full-length ER in the presence of
both E2 and OHT, but not in the absence of ligand. Furthermore,
whereas this interaction was independent of ER’s AF2 domain
(H12), disruption of the II site by the introduction of the G442H
mutation abolished receptor–peptide association (Fig. 3 B and C).
In contrast, an LxxLL peptide (19) bound equally well to both the
wild-type and G442H-mutated full-length receptor in the presence
of E2.
To elucidate which amino acid residues of the II motif are
essential for functional peptide–receptor interactions, we per-
formed limited alanine scanning mutagenesis on the II sequence
and tested variants for ER interaction in the M2H system (Fig. 3D
and E). Replacement of Phe-6, Gly-7, Ser-8, Trp-9, or Tyr-10
completely abolished receptor interaction (Fig. 3E). In contrast,
substitution of Ser-3 had a moderate effect on II binding. In the
crystal structure, the O of Ser-3 is buried and makes a single
hydrogen bond with the carboxylate of Glu-323. Although this
interaction appears to be dispensable for binding, the motif is
otherwise highly sensitive to sequence changes. Such a high degree
of sequence dependence reflects the nature of II binding, which
relies on multiple interactions with the LBD.
Enhancement of OHT-Dependent Transcriptional Activity by an Engi-
neered Coactivator. To investigate whether the II interaction
surface can be used as a functional docking site for coregulators, we
attempted to modify the behavior of the p160 coregulator TIF2
(GRIP1, SRC2, NcoA-2). TIF2 enhances ER-mediated transcrip-
tional activity in an AF2- and hormone-dependent manner (26).
TIF2’s receptor-interacting domain contains three NR boxes that
are involved in ligand-dependent NR interaction. Of these, NR box
1 and 2 have been implicated in high-affinity binding to ER (8, 27).
We inactivated NR box3 (TIF2–NR12) and replaced NR box 1 and
2 with theII sequence bymutagenesis to create TIF2II (Fig. 4A).
Fig. 1. Overall structure of ERLBD in complex with the II interaction motif. (A) Ribbon representation of the ERH12-OHT-II structure. Two perpendicular
views of the LBD monomer are shown. TheII peptide is represented by a molecular surface (cyan). Dotted lines represent regions of the structure that are poorly
defined in the experimental electron density. Secondary structure elements are labeled, and the AF2 region of the LBD (H3–H5) is colored green. (B) Composite
surface representation of the ERLBD monomer highlighting the location and extent of the known AF2 (green) and proposed II (cyan) coregulator sites. The
molecule is viewed in an identical orientation to the right ribbon representation in A.
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When Cos-7 cells were cotransfected with expression vector for
full-length ER along with reporter plasmids, we found that
coexpression of TIF2II, but not TIF2–NR12, could markedly
increase ER activity in the presence of OHT (Fig. 4B). Identical
behavior was also observed with a truncated ER lacking the AF1
domain (ER–DEF; data not shown). Similar results were ob-
served in HuH7 and HeLa cells. As expected, when the G442H
mutant receptor was analyzed under similar conditions, the mod-
ified TIF2II failed to increase ER activity in the presence ofOHT,
whereas the observed coactivation effect of wild-type TIF2 was
unaffected (data not shown).
Mutation of II Surface Alters ER’s Sensitivity to Coregulators. Fi-
nally, we examined whether mutations of the II-binding surface
are able to affect ER’s transcriptional behavior. The transactiva-
tion characteristics of the G442H mutant receptor were studied by
using either an ERE-luciferase (full-length ER) or a Gal4-
responsive (ERDEF) reporter assay. The full-lengthwild-type and
mutant receptors responded in an identical manner to E2. Surpris-
ingly, the mutant receptor exhibited a substantial increase in
transcriptional activity in response to OHT when TIF2 was coex-
pressed (Fig. 4C). Removal of AF1 resulted in similar behavior for
the wild-type or mutant receptors regardless of whether TIF2 was
coexpressed (data not shown). However, although the wild-type
receptor requires AF2 for reporter activation, the G442H mutant
responds to the addition of TIF2 even in the absence of H12 (Fig.
4D). These data suggest that the II-binding surface mediates the
observed OHT response via TIF2 itself or via unknown cellular
coregulators that antagonize TIF2’s effects.
Discussion
Comparisonwith Known Interaction Sites.The structureofERLBD
in complex with the phage display-derived II motif defines a
unique interaction surface that is distinct from theAF2 recruitment
site. The ability of the II motif to recognize ER regardless of the
bound ligand derives from the fact that its binding site is located in
a region of the LBD that is not affected by the distinct conforma-
tional effects induced by receptor agonists and antagonists. Previ-
Fig. 2. Molecular detail of II peptide interaction site. (A) View of the peptide interaction site. The II peptide is shown in stick form with cyan carbons. LBD residues
that make key contacts with the peptide are represented in ball-and-stick form with green carbons. (B) Schematic representation of the interactions made by the II
peptide. The II peptide (purple bonds) and LBD residues (black bonds) are shown. Water molecules are depicted as cyan spheres. For clarity, only intermolecular
hydrogen bonds are shown (dotted lines). Van der Waals contacts are represented by green spokes radiating between interacting residues. Figure produced with the
program LIGPLOT (33). (C) Surface representation of II site. The molecular surface of ERH12 is shown and colored according to residue type (purple, hydrophobic;
red, negative; blue, positive; yellow, polar; white, glycine). Binding site is viewed as inA. (D) Alignment of ER and ER sequences in the vicinity of the II binding site.
Secondary structural elements and sequence numbering for ERare shown along the top. Those residues that participate in hydrogen-bonded or nonpolar interactions
with the II motif are represented asterisks and circles respectively. Key sequence differences are boxed. (E) Binding of mutant E2-liganded ERLBDs. Sensorgrams
obtained from injection of 1 M wild-type and mutant ERLBDs over a surface immobilized with II peptide. (Inset) Maximum binding response for each mutant to
control SRC2–2 (LxxLL) peptide and II peptide coated sensor chips. Responses shown are after 2-min continuous injection at a flow rate of 5 lmin1.
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ous studies have shown that the AF2 region of the LBD serves as
the primary docking site for coactivators and corepressors (4–8, 12,
13). The II site identified here is located on the opposite face of
the LBD (Fig. 1B). Both surfaces are predominantly hydrophobic
in character but differ in topology. The LxxLL binding groove is
compact, encompasses a relatively small surface area (450 Å2), and
is conserved in most NRs. In contrast, the II site covers a larger
area (650 Å2) and is specific to ER. The concave II binding
surface incorporates conserved regions of the LBD that flank the
entrance to a channel that leads to the buried hormone binding
cavity. Binding of theII peptide blocks the entrance to this channel
and creates a 300-Å3 water-filled chamber. It is noted this chamber
corresponds to the so-called ‘‘second-binding site’’ that has been
evaluated as an alternative ligand-binding cavity (28). However, no
experimentally validated function has been attributed to this region
of ERLBD, and its role in ligand-binding remains controversial.
Consequently, it is highly unlikely that the II site is involved in
binding small molecule ligands.
Biological Significance of the II Sequence. What is the likelihood
that the II sequence represents a previously unknown, biologically
relevant recruitment motif? In the original phage display study, the
II motif was only observed once and, therefore, no consensus
information is available (16). Our mutagenesis studies demonstrate
Fig. 3. ER-peptide interaction in mammalian cells. Interac-
tion of GAL4-DBD-tagged II with VP16-tagged ERs. Full-
length ER (A), ERH12 (B), and ERG442H (C). (D and E)
Amino acid requirements for II interaction. (D) Amino acid
sequences of peptides used. (E) Mammalian two-hybrid re-
ceptor binding assay of GAL4-DBD-tagged wild type and mu-
tant peptides to VP16-ER wild type. Binding of the II and
LxxLL peptides were evaluated both in the absence of ligand
(NH) and in the presence of E2 and OHT. Normalized luciferase
activity is shown.
Fig. 4. Enhancement of tamoxifen-dependent transcrip-
tional activity. (A) Schematic representation of NR-box
modified coregulator TIF2 containing the II peptide se-
quence. (B) Cell-based reporter assay of transcriptional ac-
tivity of engineered TIF2 variants in the presence of full-
length ER. (C and D) Reporter activity of wild-type and
mutant ER in the presence of 100 nM OHT. Data are pre-
sented as percent activation, where the activity of full-
length ER (C) and ERDEFH12 (D) are set to 100%.
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that its interaction with ER is highly sequence-dependent. Data-
base searches with either the II sequence or a redundant motif
based on the binding mode observed in the crystal structure do not
yield any obvious homologies. Based on the apparent lack of key
hotspots within the sequence, we currently favor a model in which
the II peptide acts as a structural, rather than sequence mimic of
the true interaction partner. Consequently, the possibility that
elements of the II motif are incorporated into a nonlinear
recognition module, formed by discontinuous regions of primary
sequence, cannot be ruled out.
II Interaction Surface: A Possible Coregulator Recruitment Site? The
question remains as to whether the II motif acts as a fortuitous
conformational probe or an actual mimic of a bona fide ER
interaction partner? Norris et al. (18) demonstrated that II is able
to inhibit the partial agonist activity ofOHTwhile having aminimal
effect on E2-mediated transcription. This observation strongly
suggests that II’s cognate binding surface on ER represents an
important control site that is involved in regulating receptor activity
under certain conditions. Short peptides that act as antagonists of
protein-protein interactions have been isolated from naive libraries
for a number of systems. Subsequent structural analysis has shown
that the peptide binding site overlaps with that of a known binding
partner (29). In the case of II, the crystal structure of the complex
indicates that peptide binding to the isolated LBD does not induce
any significant conformational changes. This finding suggests that
II’s antagonistic properties are manifested by a direct steric effect
in which the peptide occludes a key binding site. At this stage, it is
unclear whether the II site is a docking surface for another region
of ER (i.e., involved in intramolecular domain signaling) or for an
as yet unidentified coregulator. The coactivator engineering exper-
iments clearly demonstrate that the II binding surface can serve
as a valid receptor–coregulator interaction site. By replacing the
NR-boxLxxLL regions of TIF2 with the II sequence, we gener-
ated a coactivator (TIF2II) that could be recruited to the II
surface by both agonist and antagonist-bound ER in an AF1AF2-
independent fashion.
Our preliminary functional analysis indicates that the II surface
may play a role in ER’s sensitivity to coregulators in the presence
of selective ER receptor modulators such as OHT (Fig. 4C). No
differences in behavior were observed between wild-type and
II-mutated ER in the presence of E2. This ligand-dependency
mirrors the previously reported antagonistic effects of the II
peptide on E2- and OHT-dependent receptor activity (18). The
surprising result that the TIF2-mediated enhancement of OHT
activity seen for the G442H mutant requires a functional AF2
H12F domain only in the context of the full-length ER, but not in
the context of the ER DEF, reinforces the idea that the functional
interplay between different ER domains and coregulators deter-
mines the transcriptional properties of the wild type receptor (30).
Furthermore, our demonstration that disruption of the II binding
site enhanced rather than decreased the response to TIF2 does not
necessarily contradict the currently held view that TIF2 acts pri-
marily as a coactivator. Although TIF2 coactivator function is
usually associated with recruitment to a functional AF12 surface,
targeting to other surfaces cannot be discounted. Recent studies by
Yamamoto and coworkers (31, 32) discovered a context-dependent
corepressor function in TIF2, which may indeed account for the
effect seen in our study. Alternatively, TIF2’s role could be indirect
and mediated by either endogenous coregulators known to coop-
erate with TIF2 (e.g., CBPp300, CARM-1) or unidentified core-
pressors that bind directly to the II surface. Indeed, although our
coregulator engineering experiment targeted a coactivator to the
II surface, similar experiments utilizing an engineered corepressor
would probably have illustrated that the II site may alternatively
be involved in corepressor binding.
In summary, the site identified in this study appears to be
involved inmaintaining a reduced level of receptor activation in the
presence of TIF2. Further studies are required to establish whether
other recognized or unrecognized ER coactivators and corepres-
sors also display sensitivity to the disruption of this unique control
surface.
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